Xlife Sciences publishes annual results 2021 and outlook 2022 - Seite 2

Further strengthening of Xlife Sciences' Management Team through the appointment of Dr. Frank Plöger as Chief Scientific Officer and Carl von Halem as Chief Financial Officer as well as the expansion of the scientific Advisory Board with additional members.

Oliver R. Baumann, CEO of Xlife Sciences, comments: 'We look back on a successful 2021, in which we have made progress in every area. Moreover, we reached an important milestone shortly after the balance sheet date, namely the change from the Munich Stock Exchange to the new SME trading segment 'Sparks' of the SIX Swiss Exchange. Thanks to the great commitment of all employees and the trust of the shareholders, we were able to successfully implement this strategically important project for Xlife Sciences on February 11, 2022, when the first trading day on the SIX took place. We are convinced that this move to a regulated equity trading market, with correspondingly high transparency and communication requirements, is in the interest of existing and new investors.'

Financial Key Figures 2022:

Xlife Sciences more than doubled its sales to a total of CHF 0.8 million.

The consolidated financial statements according to IFRS (true & fair view) closed with CHF 53.2 million, the individual financial statements according to commercial law with CHF -4.3 million.

Earnings per share (basic) amounted to CHF 11.30 (2020: CHF 5.53 per share).

Xlife Sciences was able to increase its consolidated equity attributable to the shareholders of the company to CHF 210.8 million.

Xlife Sciences has total assets of CHF 480 million at the end of 2021 (2020: CHF 185 million).

The complete Annual Report 2021 including the annual financial statements is available for download in German at www.xlifesciences.ch/news-kennzahlen (a full English translation will be available in a few days via www.xlifesciences.ch/en/news-and-key-figures).

Outlook 2022: